TP53 缺失通过上调 NF-κB-IFN-β-MHC-Ia 信号促进骨肉瘤对 NK 细胞的抵抗
TP53 Loss Elevates NF-κB-IFN-β-MHC-Ia Signaling to Promote NK Cell Resistance in Osteosarcoma.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Local Tumor Necrosis Factor Alpha Exposure Inhibits Posterolateral Fusion Rates in a Rat Model.
Local Tumor Necrosis Factor Alpha Exposure Inhibits Posterolateral Fusion Rates in a Rat Model.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
术后 TNF-水平的短暂局部升高会显著损害大鼠的后外侧融合。限制融合部位早期 TNF-活性可能改善关节融合结局,尤其是在炎症特征升高的患者中。
确定暴露于TNF-水平是否影响间充质干细胞(MSC)的成骨分化,以及融合部位短暂、局部的TNF-是否影响大鼠模型中的后外侧关节融合术。背景数据摘要:已证实退行性脊柱病变、假关节形成和全身性炎症中肿瘤坏死因子-(TNF-)升高。然而,局部局限性TNF-暴露对后续关节融合术的影响仍不完全清楚。
随机、临床前动物研究。MSCs在体外用TNF-暴露进行检测。对35只Wistar Kyoto雄性大鼠进行了L4-L5双侧后外侧融合。两组均使用脱矿骨基质(DBM)进行融合,但治疗组还在可吸收胶原海绵上接受了低剂量TNF-(20 uL的50 ng/mL)。第2天和第4天处死的动物,其局部融合块被采集并通过ELISA进行细胞因子分析。血清也通过心脏穿刺采集。第4周处死的动物通过手动触诊和microCT评估融合情况,以及通过ELISA检测血清细胞因子水平。
TNF-以剂量依赖性方式抑制MSC成骨,从0.1 ng/mL开始。与对照组相比,治疗组术后第2天(POD 2)融合块内TNF-蛋白升高(P <0.05),而IL-1水平保持不变。在第4周,手动触诊显示4/5对照动物实现融合,而所有TNF-治疗动物均未融合(P=0.048)。Micro-CT和组织学分析显示,4/5对照动物实现双侧融合,而TNF-动物为1/5,其余表现为单侧融合或无融合(P = 0.286)。
To determine whether exposure to TNF- levels affects Mesenchymal stem cell (MSC) osteogenic differentiation and if brief, localized TNF- at the fusion site affects posterolateral arthrodesis in a rat model. SUMMARY OF BACKGROUND DATA: Elevated tumor necrosis factor- (TNF- ) has been shown in degenerative spine pathology, pseudarthrosis, and systemic inflammation. Yet the effect of local localized TNF- exposure on subsequent arthrodesis remains incompletely understood.
MSCs were examined in vitro with TNF- exposure. Bilateral posterolateral fusions at L4-L5 were performed on 35 Wistar Kyoto male rats. Demineralized bone matrix (DBM) was used for fusion in both groups, but the treatment group also received a low dose of TNF- (20 uL of 50 ng/mL) on an absorbable collagen sponge. Animals sacrificed at day 2 and day 4 had the local fusion mass harvested and processed for cytokine analysis with ELISA. Serum was also collected by cardiac puncture. Animals sacrificed at 4 weeks were assessed by manual palpation and microCT for fusion, as well as serum cytokine levels with ELISA.
TNF- suppressed MSC osteogenesis in a dose-dependent manner, starting at 0.1 ng/mL. TNF- protein rose within the fusion mass at postoperative day (POD) 2 in the treatment group compared to controls (P <0.05), while IL-1 levels remained unchanged. At 4 weeks, manual palpation demonstrated fusion in 4/5 control animals, and no fusion in any TNF- -treated animal (P=0.048). Micro-CT and histological analysis revealed bilateral fusion in 4/5 controls compared with 1/5 TNF- animals, with the remainder showing unilateral or no fusion (P = 0.286).
A brief, localized increase in TNF- levels after surgery significantly impairs posterolateral fusion in rats. Limiting early TNF- activity at the fusion site may improve arthrodesis outcomes, particularly in patients with elevated inflammatory profiles.
MEMBER ACCOUNT
登录成功会直接打开下一页。